Update on hepatitis B virus infection.
Submit a Manuscript: doc.guandang.net Desk: doc.guandang.net: 10.3748/wjg.v20.i37.13293
© 2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol 2014 October 7; 20(37): 13293-13305
ISSN 1007-9327 (print) ISSN 2219-2840 (online)
TOPIC HIGHLIGHT
WJG 20th Anniversary Special Issues (9): Hepatitis B virus
Update on hepatitis B virus infection
Chan Ran You, Sung Won Lee, Jeong Won Jang, Seung Kew Yoon
Chan Ran You, Sung Won Lee, Jeong Won Jang, Seung Kew Yoon, Division of Hepatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 137-701, South Korea
Author contributions: Yoon SK conducted the review and wrote the manuscript; You CR, Lee SW and Jang JW revised the manuscript.
Correspondence to: Seung Kew Yoon, MD, PhD, Professor, Division of Hepatology, Department of Internal Medicine, Col-lege of Medicine, Seoul St. Mary’s Hospital, The Catholic Uni-versity of Korea, #505 Banpodong, Seocho-gu, Seoul 137-701, South Korea. yoonsk@catholic.ac.kr
Telephone: +82-2-22587534 Fax: +82-2-5369559
Received: November 29, 2013 Revised: March 18, 2014 Accepted: April 5, 2014
Published online: October 7, 2014
test for detection of drug resistance still has limitations in identifying the different substitutions present in the same viral genome, the development of a new virologic test to overcome this limitation is necessary. Among the predictive factors associated with response to pegylat-ed interferon (PEG-IFN) therapy, hepatitis B surface antigen quantification is considered to be a surrogate marker for monitoring response to PEG-IFN. Current practice guidelines stress the importance of profound and durable HBV viral suppression in the treatment of CHB patients. To this end, it is essential to choose a potent antiviral drug with a low risk of resistance for initial treatment of CHB to achieve sustained virological response. This review highlights recent advances in the understanding of the immunopathogenesis of HBV and currently available and developing treatment strategies against HBV infection.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
Abstract
Chronic infection with hepatitis B virus (HBV) leads to the development of hepatocellular carcinoma and/or chronic liver failure. Despite extensive research, the im-munopathogenesis is not completely understood. Viral persistence and clinical outcomes following HBV infec-tion depend on viral factors and host factors; including genetic factors that determine a host’s immune mecha-nisms. The primary goal of chronic hepatitis B (CHB) treatment is to eradicate HBV or to at least maintain suppression of HBV replication. Despite recent advances in anti-viral agents for chronic HBV infection, complete eradication of the virus has been difficult to achieve. Agents for the treatment of CHB are divided mainly into two groups: immunomodulating agents and antiviral nucleos(t)ide analogues (NAs). Although NAs are safe, effective and easily administered orally, their long-term use poses the risk of drug resistance. Currently, inter-national evidence-based guidelines have been devel-oped to support physicians in managing CHB patients. However, treatment of patients with drug resistance is still challenging, as only a few classes of anti-HBV drugs are available and cross-resistance between drugs can occur. In addition, as the currently available genotypic
Key words: Hepatitis B virus; Chronic hepatitis B; Nucleos(t)ide analogue; Pegylated interferon; Antiviral therapy
Core tip: The primary goal of chronic hepatitis B (CHB) treatment is to eradicate hepatitis B virus (HBV) or to at least maintain suppression of HBV replication. To this end, it is essential to better understand the immuno-pathogenesis of CHB, although it has yet to be further elucidated. More practically, it is of great importance to choose a potent antiviral drug with a low risk of resis-tance for initial treatment of CHB to achieve sustained virological response. This review highlights recent advances in the understanding of the immunopatho-genesis of HBV and currently available and developing treatment strategies for HBV infection.
You CR, Lee SW, Jang JW, Yoon SK. Update on hepatitis B vi-rus infection. World J Gastroenterol 2014; 20(37): 13293-13305 Available from: URL: doc.guandang.net DOI: doc.guandang.net

Hepatitis B virus infection_医药卫生_专业资料。乙型病毒性肝炎...c Consensus statement on the management of chronic hepatitis B: 2008 update...
Hepatitis B Virus Infection Reduces Fertilization Ability During In Vitro ...Hum Reprod Update 6:432–441. Wang XR, Qu ZQ, Li XD, Liu HL, He ...
Special Populations with Hepatitis B Virus Infection Marion G. Peters Treatment of patients with chronic hepatitis B virus (HBV) infection who have ...
doi:10.1111/j.1440-1746.2007.05216.x H E PAT O L O G Y Association of chronic hepatitis B virus infection with insulin resistance and hepatic ...
hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123 (6), 1831–1838. Lau, G.K., Piratvisuth, T., Luo, K.X....
Baseline characteristics of 242 patients with hepatitis B virus genotype C infection Inactive carrier Case number Sex F M P value Age (years) P value ...
Hepatitis B virus chronic infection may also be a risk factor in HBsAg-negative hepatocellular carcinoma The issue of persisting HBV infections in patients ...
Perspectives on China Hepatitis B Prevention Hepatitis B Virus Infection乙型肝炎病毒感染: Worldwide Burden of Disease全球范围的疾病负担 ? 2 billion people ...
EB, Dieterich DT, Han SH, et al: A treatment of algorithm for the management of chronic hepatitis B virus infection in the United States: An update....
Polymerase chain reaction; Restriction fragment length polymorphism (RLFP); Bai nationality in China Hepatitis B virus (HBV) infection is a global health ...
热门文档